miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology-Reference-Cited by-同舟云学术

miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology

Published:2017-04-27 Issue:8 Volume:125 Page:635-643
ISSN:1934-662X
Container-title:Cancer Cytopathology
language:en
Short-container-title:Cancer Cytopathology

Author:

Cappellesso Rocco¹^ORCID,Galasso Marco²,Nicolè Lorenzo¹,Dabrilli Paolo¹,Volinia Stefano²,Fassina Ambrogio¹

Affiliation:

1. Surgical Pathology and Cytopathology Unit, Department of Medicine; University of Padua; Padua Italy

2. Laboratorio per le Tecnologie delle Terapie Avanzate, Department of Morphology, Surgery, and Experimental Medicine; University of Ferrara; Ferrara Italy

Funder

Italian Association for Cancer Research

Ministry of University Education and Research

EPIGEN

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncy.21869/fullpdf

Reference36 articles.

1. Epithelial-mesenchymal transition in malignant mesothelioma;Fassina;Mod Pathol.,2012

2. The European mesothelioma epidemic;Peto;Br J Cancer.,1999

3. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group;Husain;Arch Pathol Lab Med.,2013

4. Lumican is overexpressed in lung adenocarcinoma pleural effusions;Cappellesso;PLoS One.,2015

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Recommendations for Cell-Free DNA Assay Validations;The Journal of Molecular Diagnostics;2023-12

2. Melodic maestros: Unraveling the role of miRNAs in the diagnosis, progression, and drug resistance of malignant pleural mesothelioma;Pathology - Research and Practice;2023-10

3. Optimal isolation of extracellular vesicles from pleural fluid and profiling of their microRNA cargo;Journal of Extracellular Biology;2023-10

4. MicroRNA Biomarkers of Malignant Mesothelioma;Genomic and Epigenomic Biomarkers of Toxicology and Disease;2022-04-27

5. Pathophysiology roles and translational opportunities of miRNAs in mesothelioma;MicroRNA in Human Malignancies;2022